none taken kates. gd to see u on here and appreciate ur ta on this amongst others.
like you mentioned, you really have to be holding shares before ann are out. a licensing agreement will easily double the sp within a day for micro-cap pharma coy.
from e exchange of emails as well as previous ann from coy, i do expect more license agreements with big names by years end and Dr Cummings doesnt rule out one before the AGM.
southern cross equities recommends a spec buy in their report; valuing Anteo at $0.13 per share base case and $0.24 optimistic case using a high-discount-rate (ie 25%) DCF valuation. their target price of $0.13 sits at their base case valuation. they see potential for a rerating of Anteo as further licensing deals emerge and early revenue is generated from Bangs and Merck.
none taken kates. gd to see u on here and appreciate ur ta on...
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.001(3.67%) |
Mkt cap ! $52.28M | |||
| Open | High | Low | Value | Volume |
| 2.2¢ | 2.3¢ | 2.1¢ | $7.812K | 349.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 828094 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 1102151 | 4 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| ADO (ASX) Chart |